Rabbit Polyclonal EGFR phospho Y1148 antibody. Suitable for ICC, WB and reacts with Human samples. Cited in 1 publication. Immunogen corresponding to Synthetic Peptide within Human EGFR phospho Y1148.
pH: 7.3
Preservative: 0.05% Sodium azide
Constituents: PBS, 0.1% BSA
ICC | WB | |
---|---|---|
Human | Tested | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/250 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/1000 | Notes - |
Select an associated product type
The protein expressed by the EGFR gene functions as a receptor tyrosine kinase, binding with ligands from the EGF family to activate several signaling cascades that translate extracellular signals into cellular responses. Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen, BTC/betacellulin, epiregulin, and HBEGF. Ligand binding triggers receptor dimerization and autophosphorylation, recruiting adapter proteins like GRB2 and activating complex downstream signaling pathways such as RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC, and STATs, and possibly the NF-kappa-B cascade. EGFR also directly phosphorylates proteins like RGS16 and MUC1, influencing various cellular processes including its coupling with G protein-coupled receptor signaling and cell migration through interaction with CCDC88A/GIV. Isoform 2 of EGFR may act as an antagonist to EGF actions. In microbial infection, EGFR also serves as a receptor facilitating hepatitis C virus (HCV) entry into hepatocytes by promoting CD81-CLDN1 receptor complexes and enhancing membrane fusion with HCV envelope glycoproteins. This supplementary information is collated from multiple sources and compiled automatically.
ERBB, ERBB1, HER1, EGFR, Epidermal growth factor receptor, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1
Rabbit Polyclonal EGFR phospho Y1148 antibody. Suitable for ICC, WB and reacts with Human samples. Cited in 1 publication. Immunogen corresponding to Synthetic Peptide within Human EGFR phospho Y1148.
pH: 7.3
Preservative: 0.05% Sodium azide
Constituents: PBS, 0.1% BSA
The antibody has been negatively preadsorbed using (i) a non phosphopeptide corresponding to the site of phosphorylation to remove antibody that is reactive with non-phosphorylated epidermal growth factor receptor (EGFR), and (ii) a generic tyrosine phosphorylated peptide to remove antibody that is reactive with phosphotyrosine, irrespective of the sequence. The final product is generated by affinity chromatography using an EGFR-derived peptide that is phosphorylated at tyrosine 1148.
EGFR or Epidermal Growth Factor Receptor is a transmembrane glycoprotein that acts as a receptor for members of the epidermal growth factor family. Known alternatively as ErbB1 or HER1 this receptor has an approximate molecular weight of 170 kDa. EGFR is expressed in various cell types notably on epithelial cells and can influence multiple cellular processes through its kinase activity. It participates in the regulation of cell growth multiplication and survival by activating its kinase domain upon ligand binding.
The EGFR protein plays an important role in cellular communication and signaling processes. EGFR pairs with other receptor family members to form active dimers or even higher-order complexes which in turn initiate intracellular signaling cascades. Through these complexes EGFR influences many processes including cell differentiation and repair. This function of EGFR makes it an integral part of mammalian biology affecting how cells respond to their environment by mediating changes in gene expression.
EGFR is a central player in the MAPK and PI3K/Akt signaling pathways. Alongside other protein partners like KRAS and PI3 kinase it contributes to transmitting signals from the cell surface to the nucleus affecting gene transcription and cell behavior. These pathways are important for normal cell growth and division and aberrations in these pathways can lead to excessive or insufficient cell proliferation.
EGFR is pertinent to cancer biology including non-small cell lung cancer and glioblastoma where mutations or overexpression of the receptor frequently occur. It connects to proteins such as PTEN and BRAF which influence tumor progression and response to targeted therapies. EGFR's involvement in these disorders highlights its significance as a therapeutic target since it can be manipulated to alter disease progression.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Immunocytochemical analysis of EGFR (pY1148) on A549 cells. The cells were fixed with 4% paraformaldehyde, permeabilized with 0.25% Triton™ X-100. The cells were labeled with ab5651 at 1/250 dilution in 1% BSA and incubated for 3 hours at room temperature followed by Alexa Fluor 488 Goat Anti-Rabbit IgG Secondary Antibody at a dilution of 1/400 (Panel a: green). Nuclei (Panel b: blue) were stained DAPI. (Panel c: red) F-actin was stained with Alexa Fluor 594 Phalloidin. Panel d is a merged image showing cytoplasmic localization. Panel e shows no primary antibody control.
Blocking buffer: 5% BSA-TBST
The phosphopeptide corresponding to EGFR [pY1148] blocks the signal.
All lanes: Western blot - Anti-EGFR (phospho Y1148) antibody (ab5651) at 1/1000 dilution
Lane 1: A431 cells unstimulated with no peptide
Lane 2: A431 cells stimulated with 200 ng/mL EGF for 15 minutes with no peptide
Lane 3: A431 cells stimulated with 200 ng/mL EGF for 15 minutes with non-phosphopeptide corresponding to the phosphopeptide immunogen
Lane 4: A431 cells stimulated with 200 ng/mL EGF for 15 minutes with a generic phosphotyrosine-containing peptide
Lane 5: A431 cells stimulated with 200 ng/mL EGF for 15 minutes with phosphopeptide immunogen
All lanes: goat F(ab’)2 anti-rabbit IgG HRP conjugate
Predicted band size: 134 kDa
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com